Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interventional, Randomized, Double-blind, Parallel-group, Healthy Subject, Single Dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Eptinezumab Manufactured Using Two Different Cell Lines

NCT05074459 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT05074459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05074459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interventional, Randomized, Double-blind, Parallel-group, Healthy Subject, Single Dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Eptinezumab Manufactured Using Two Different Cell Lines
Lead sponsor
H. Lundbeck A/S
Phase
Phase 1
Overall status
Completed
Start date
September 27, 2021
Completion date
July 18, 2022
Enrollment
84 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants